We read with great interest the article by Mc Entee et al. [
[1]
] in which they conducted a single-institutional retrospective study that included
654 patients with non-metastatic colorectal cancer (CRC), to illustrate the impact
of extramural venous invasion (EMVI) on the long-term survival outcomes of these patients.
The authors concluded that the presence of EMVI was significantly associated with
poor prognosis of CRC patients independent of histopathological characteristics. Considering
the importance of EMVI for predicting CRC recurrence and determining the necessity
of postoperative adjuvant chemotherapy (AC), the implications and novelty of this
study should be highlighted. However, we would like to raise the following comments.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Surgical OncologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Extramural venous invasion (EMVI) in colorectal cancer is associated with increased cancer recurrence and cancer-related death.Eur J Surg Oncol. 2022; 48: 1638-1642https://doi.org/10.1016/j.ejso.2022.02.013
- The short-term and oncologic outcomes of younger VS older colorectal cancer patients undergoing primary surgery: a propensity score matching analysis.BMC Cancer. 2022; 22: 153https://doi.org/10.1186/s12885-022-09246-4
- Prognostic significance of the lymph node ratio in stage IV colorectal cancer patients who have undergone curative resection.Ann Surg Oncol. 2015; 22: 1513-1519https://doi.org/10.1245/s10434-014-4184-6
- Adjuvant chemotherapy improves prognosis of resectable stage IV colorectal cancer: a comparative study using inverse probability of treatment weighting.Ther Adv Med Oncol. 2019; 111758835919838960https://doi.org/10.1177/1758835919838960
- Capecitabine as adjuvant treatment for stage III colon cancer.N Engl J Med. 2005; 352: 2696-2704https://doi.org/10.1056/NEJMoa043116
- Efficacy of adjuvant chemotherapy after resection of pulmonary metastasis from colorectal cancer: a propensity score-matched analysis.Eur J Cancer. 2019; 106: 69-77https://doi.org/10.1016/j.ejca.2018.10.003
- Propensity scores and the surgeon.Br J Surg. 2006; 93: 389-394https://doi.org/10.1002/bjs.5265
- Systematic review of prognostic factors related to overall survival in patients with stage IV colorectal cancer and unresectable metastases.World J Surg. 2011; 35: 684-692https://doi.org/10.1007/s00268-010-0891-8
- Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature.Ann Surg Oncol. 2011; 18: 3252-3260https://doi.org/10.1245/s10434-011-1951-5
- Prognostic factors associated with primary cancer in curatively resected stage IV colorectal cancer.J Cancer Res Clin Oncol. 2014; 140: 435-441https://doi.org/10.1007/s00432-013-1580-4
Article info
Publication history
Published online: August 19, 2022
Accepted:
August 11,
2022
Received:
June 13,
2022
Identification
Copyright
© 2022 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
